首页> 美国卫生研究院文献>other >An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account
【2h】

An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account

机译:一个准确的前列腺癌预言家使用七基因标签加上Gleason评分并以细胞类型异质到账户

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

One of the major challenges in the development of prostate cancer prognostic biomarkers is the cellular heterogeneity in tissue samples. We developed an objective Cluster-Correlation (CC) analysis to identify gene expression changes in various cell types that are associated with progression. In the Cluster step, samples were clustered (unsupervised) based on the expression values of each gene through a mixture model combined with a multiple linear regression model in which cell-type percent data were used for decomposition. In the Correlation step, a Chi-square test was used to select potential prognostic genes. With CC analysis, we identified 324 significantly expressed genes (68 tumor and 256 stroma cell expressed genes) which were strongly associated with the observed biochemical relapse status. Significance Analysis of Microarray (SAM) was then utilized to develop a seven-gene classifier. The Classifier has been validated using two independent Data Sets. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively based on independent testing. These results indicated that our prognostic model that includes cell type adjustments and using Gleason score and the seven-gene signature has some utility for predicting outcomes for prostate cancer for individual patients at the time of prognosis. The strategy could have applications for improving marker performance in other cancers and other diseases.
机译:前列腺癌预后生物标记物开发中的主要挑战之一是组织样本中的细胞异质性。我们开发了客观的聚类相关性(CC)分析,以鉴定与进展相关的各种细胞类型中的基因表达变化。在聚类步骤中,通过混合模型与多元线性回归模型(其中使用细胞类型百分比数据进行分解)组合的混合模型,基于每个基因的表达值对样本进行聚类(无监督)。在相关步骤中,使用卡方检验来选择潜在的预后基因。通过CC分析,我们确定了324个显着表达的基因(68个肿瘤和256个基质细胞表达的基因),这些基因与观察到的生化复发状态密切相关。然后利用微阵列的重要性分析(SAM)来开发七基因分类器。分类器已使用两个独立的数据集进行了验证。总体预测准确性和灵敏度分别为71%和76%。根据独立测试,将格里森和添加到七基因分类器中的预测准确性和灵敏度分别提高到83%和76%。这些结果表明,我们的预后模型包括细胞类型调整以及使用格里森评分和七基因标记,可在预测预后时对个别患者的前列腺癌结局进行预测。该策略可能具有改善其他癌症和其他疾病中标记物性能的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号